Localized scleroderma (LS), also known as morphea, is the most frequent form of scleroderma in childhood and is grouped into five subtypes: circumscribed morphea, linear scleroderma, generalized morphea, pansclerotic morphea, and a mixed subtype, where a combination of two or more of the previous subtypes is present. Linear scleroderma is the most frequent subtype in childhood, and when it involves the face (LSF), it may cause aesthetic and functional abnormalities, sometimes complicated by hemifacial atrophy.
An early diagnosis, an appropriate assessment, and an effective treatment may slow the disease progression and prevent ophthalmological and neurological complications.
Studies over the past few years have added interesting contributions on new outcome measures for the disease assessment and monitoring. Indeed, a recent randomized placebo-controlled trial has confirmed the important role of methotrexate for this particular subtype of scleroderma.
Arkachaisri T, et al. The localized scleroderma skin severity index and physician global assessment of disease activity: a work in progress toward development of localized scleroderma outcome measures. J Rheumatol. 2009;36:2819.PubMedCrossRefGoogle Scholar
Li SC, Liebling MS. The use of Doppler ultrasound to evaluate lesions of localized scleroderma. Curr Rheumatol Rep. 2009;11:205.PubMedCrossRefGoogle Scholar
Martini G, et al. Juvenile-onset localized scleroderma activity detection by infrared thermography. Rheumatology (Oxford). 2002;41:1178.CrossRefGoogle Scholar
Weibel L, et al. Laser Doppler flowmetry for assessing localized scleroderma in children. Arthritis Rheum. 2007;56:34.CrossRefGoogle Scholar
Zulian F, et al. A new computerized method for the assessment of skin lesions in localized scleroderma. Rheumatology (Oxford). 2007;46:856.CrossRefGoogle Scholar
Kreuter A, Altmeyer P, Gambichler T. Treatment of localized scleroderma depends on the clinical subtype. Br J Dermatol. 2007;156:1362.CrossRefGoogle Scholar
Zulian F, et al. Methotrexate treatment in juvenile localized scleroderma. A randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 2011;63:1998.PubMedCrossRefGoogle Scholar
Li SC, et al. Development of consensus treatment plans for juvenile localized scleroderma: a roadmap toward comparative effectiveness studies in juvenile localized scleroderma. Arthritis Care Res. 2012;64:1175.Google Scholar
Zulian F, et al. A long-term follow-up study of methotrexate in juvenile localized scleroderma (morphea). J Am Acad Dermatol. 2012;67:1151.PubMedCrossRefGoogle Scholar
Martini G, et al. Successful treatment of severe or methotrexate-resistant juvenile localized scleroderma with mycophenolate mofetil. Rheumatology (Oxford). 2009;48:1410.CrossRefGoogle Scholar
Orzechowski NM, et al. Health-related quality of life in children and adolescents with juvenile localized scleroderma. Rheumatology (Oxford). 2009;48:670.CrossRefGoogle Scholar
Palmero ML, et al. En coup de sabre scleroderma and Parry-Romberg syndrome in adolescents: surgical options and patient-related outcomes. J Rheumatol. 2010;37:2174.PubMedCrossRefGoogle Scholar